Dr. Cihan TAŞTAN
Founding Director (CEO)
Cihan Taştan graduated from METU Molecular Biology and Genetics in 2011 as a “High Honor” student. In the same year, he was awarded a full scholarship to do his PhD in Microbiology-Immunobiology at New York University. He completed his Ph.D. thesis on the relationships between human immune system cells and bacteria species in our body in September 2017. He received the (PhD) title. In January 2015, he continued his research with the title of Pre-Doctoral Associate at The Jackson Laboratory-Genomic Medicine Institute. And he took part in the project to develop CRISPR genome modification techniques in human immune system cells.
Based on these studies, from October 2017 to October 2020, he continued his studies to produce genetically modified CAR-T cell therapies against cancer types and genetic treatments against genetic diseases (for example, Duchenne Muscular Dystrophy) as the R & D Unit Responsible at Acıbadem LabCell Cell Laboratory.
He has a wide range of knowledge and experience in synthetic biology, genetic engineering and molecular biology, covering undergraduate and doctoral periods. He is currently the founding director of the international rare diseases genetic therapy competition and the hiDNA initiative. He works genetic therapy as a director of Üsküdar University TRGENMER (Transgenic Cell Technologies and Epigenetics Application and Research Center).